Developing diagnostics for emerging and overlooked diseases.
CLIA-certified and CAP-accredited laboratory testing for endometriosis, Chagas, NCC & more!
What if endometriosis could be detected by a blood test?
EndomTest™ is now available in the US, the first non-invasive endometriosis test for the 6.5M women living with endometriosis.
Your pain isn't normal.
#Endometriosis#OverlookedButNotRare#KepheraDX
We’re proud to announce the launch of EndomTest™, the first commercially available blood test for endometriosis in the U.S. Order online at https://t.co/Op3kvw7qZC
Kephera Diagnostics CLIA-certified lab will launch two assays testing for Chagas disease in May 2023: an FDA-approved ELISA and a new, multiplex test – both detect antibodies to the parasitic agent that causes the disease. #WorldChagasDay#chagasdisease#diagnostics
Excited to announce a new contract from NIAID to develop a new test for Chagas disease. This contract will support the development and preliminary evaluation of a test that can discriminate active from successfully treated Chagas disease.
We are excited to announce our new quantitative antibody test for COVID-19 that measures your immune response after COVID-19 vaccination or infection.
Learn how to get the test here: https://t.co/qZAfAv5OWS
@KepheraDx - based in #Framingham announced that it has been approved as a CLIA certified laboratory by the Massachusetts Dept of Public Health and the U.S. Centers for Medicare and Medicaid, and is now offering COVID-19 antibody testing in Massachusetts and 44 other states.
Kephera Diagnostics is excited to announce its new CLIA laboratory has launched testing for COVID-19 antibodies. Contact us at [email protected] for details on how to submit blood samples for testing. https://t.co/P2qtGU6qIz
Happy #NationalInternDay! Investing in the next generation of life science professionals is at the core of how we fulfill our mission at the MLSC. Since its inception in 2009, the Internship Challenge has produced more than 4,300 internships at nearly 800 companies throughout MA.
Kephera Diagnostics awarded Phase II grant from the National Institute of Allergy and Infectious Diseases (NAID) for Zika virus test | FirstWord MedTech https://t.co/KNXsbHnWwz via @fwpharma
Kephera Diagnostics has been awarded a 2-year, Phase II Small Business Innovation Research (SBIR) grant by the National Institute of Allergy and Infectious Diseases (NIAID), an agency of the National Institutes of Health, to complete and launch a new t ... https://t.co/zTvqAtnYUQ
“At Kephera, we put interns in the lab to help them learn the ropes and gain the knowledge of what’s involved in the business of test development."
Interns playing a vital role during pandemic at @KepheraDx.
🔗 https://t.co/uuIqgRWeL7
We’re pleased to have interns Anton and Gabi at Kephera, through @MALifeSciences' Internship Challenge to feed our talent pipeline and help us quickly develop our antibody test for #COVID19.
To help with its research and development, #FraminghamMA-based @KepheraDx hired two interns through the MLSC’s Internship Challenge.
Read more on interns playing a vital role during the pandemic: https://t.co/eZk1D8JKRt
Check out @oaonair Healthcare, Joe Alviani chats w/Dr. Andrew Levin, Chief Executive/Chief Scientific Officer of #Framingham based Kephera Diagnostics, re: company's efforts to develop antibody test/testing kit for COVID19. https://t.co/fCLtuyKXxx
@ONeillandAssoc@Framingham_MA